These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26003086)

  • 21. Luseogliflozin inhibits high glucose-induced TGF-
    Osaka N; Mori Y; Terasaki M; Hiromura M; Saito T; Yashima H; Shiraga Y; Kawakami R; Ohara M; Fukui T; Yamagishi SI
    J Int Med Res; 2022 May; 50(5):3000605221097490. PubMed ID: 35510669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β-cells in db/db mice: The earlier and longer, the better.
    Kimura T; Obata A; Shimoda M; Okauchi S; Kanda-Kimura Y; Nogami Y; Moriuchi S; Hirukawa H; Kohara K; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Obes Metab; 2018 Oct; 20(10):2442-2457. PubMed ID: 29873444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis.
    Maeda S; Matsui T; Takeuchi M; Yamagishi S
    Diabetes Metab Res Rev; 2013 Jul; 29(5):406-12. PubMed ID: 23508966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway.
    Shirakawa J; Tajima K; Okuyama T; Kyohara M; Togashi Y; De Jesus DF; Basile G; Kin T; Shapiro AMJ; Kulkarni RN; Terauchi Y
    Diabetologia; 2020 Mar; 63(3):577-587. PubMed ID: 31897526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans.
    Miyata A; Hasegawa M; Hachiuma K; Mori H; Horiuchi N; Mizuno-Yasuhira A; Chino Y; Jingu S; Sakai S; Samukawa Y; Nakai Y; Yamaguchi JI
    Xenobiotica; 2017 Apr; 47(4):332-345. PubMed ID: 27347703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
    Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG.
    Chang HC; Yang SF; Huang CC; Lin TS; Liang PH; Lin CJ; Hsu LC
    Mol Biosyst; 2013 Aug; 9(8):2010-20. PubMed ID: 23657801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.
    Kakinuma H; Oi T; Hashimoto-Tsuchiya Y; Arai M; Kawakita Y; Fukasawa Y; Iida I; Hagima N; Takeuchi H; Chino Y; Asami J; Okumura-Kitajima L; Io F; Yamamoto D; Miyata N; Takahashi T; Uchida S; Yamamoto K
    J Med Chem; 2010 Apr; 53(8):3247-61. PubMed ID: 20302302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Luseogliflozin, A Sodium Glucose Co-transporter 2 Inhibitor, Alleviates Hepatic Impairment in Japanese Patients with Type 2 Diabetes.
    Kusunoki M; Natsume Y; Sato D; Tsutsui H; Miyata T; Tsutsumi K; Suga T; Oshida Y
    Drug Res (Stuttg); 2016 Nov; 66(11):603-606. PubMed ID: 27626603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
    Lapuerta P; Zambrowicz B; Strumph P; Sands A
    Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome.
    Rahman A; Kittikulsuth W; Fujisawa Y; Sufiun A; Rafiq K; Hitomi H; Nakano D; Sohara E; Uchida S; Nishiyama A
    J Hypertens; 2016 May; 34(5):893-906. PubMed ID: 26982381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages.
    Takahashi K; Nakamura A; Miyoshi H; Nomoto H; Kitao N; Omori K; Yamamoto K; Cho KY; Terauchi Y; Atsumi T
    Sci Rep; 2018 May; 8(1):6864. PubMed ID: 29717223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Ohtake Y; Sato T; Matsuoka H; Kobayashi T; Nishimoto M; Taka N; Takano K; Yamamoto K; Ohmori M; Higuchi T; Murakata M; Morikawa K; Shimma N; Suzuki M; Hagita H; Ozawa K; Yamaguchi K; Kato M; Ikeda S
    Bioorg Med Chem; 2012 Jul; 20(13):4117-27. PubMed ID: 22652255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.
    Yamazaki D; Konishi Y; Morikawa T; Kobara H; Masaki T; Hitomi H; Osafune K; Nakano D; Kittikulsuth W; Nishiyama A
    J Diabetes Investig; 2020 Jul; 11(4):834-843. PubMed ID: 31880858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors.
    Lin TS; Liw YW; Song JS; Hsieh TC; Yeh HW; Hsu LC; Lin CJ; Wu SH; Liang PH
    Bioorg Med Chem; 2013 Nov; 21(21):6282-91. PubMed ID: 24071445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice.
    Hata S; Okamura T; Kobayashi A; Bamba R; Miyoshi T; Nakajima H; Kitagawa N; Hashimoto Y; Majima S; Senmaru T; Okada H; Ushigome E; Nakanishi N; Takakuwa H; Sasano R; Hamaguchi M; Fukui M
    Nutrients; 2022 Aug; 14(17):. PubMed ID: 36079789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Luseogliflozin: first global approval.
    Markham A; Elkinson S
    Drugs; 2014 Jun; 74(8):945-50. PubMed ID: 24848756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
    Raskin P
    Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.